ProMIS Neurosciences Files 8-K

TL;DR

ProMIS Neurosciences filed an 8-K on Sept 3, 2025, covering financial statements and other events.

AI Summary

ProMIS Neurosciences Inc. filed an 8-K on September 3, 2025, reporting on various events. The filing includes information related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, formerly known as AMORFIX LIFE SCIENCES LTD, is incorporated in Canada and headquartered in Toronto.

Why It Matters

This 8-K filing provides updates on ProMIS Neurosciences' corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting on corporate events and financial statements, not indicating any immediate significant risks.

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• AMORFIX LIFE SCIENCES LTD (company) — Former company name
• September 3, 2025 (date) — Date of report
• Toronto, Ontario (location) — Principal executive offices

FAQ

Filing Documents

• pmn-20250903x8k.htm (8-K) — 38KB
• pmn-20250903xex99d1.htm (EX-99.1) — 24KB
• pmn-20250903xex99d1001.jpg (GRAPHIC) — 7KB
• 0001558370-25-011845.txt ( ) — 202KB
• pmn-20250903.xsd (EX-101.SCH) — 4KB
• pmn-20250903_def.xml (EX-101.DEF) — 3KB
• pmn-20250903_lab.xml (EX-101.LAB) — 17KB
• pmn-20250903_pre.xml (EX-101.PRE) — 12KB
• pmn-20250903x8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 3, 2025, ProMIS Neurosciences Inc. (the "Company") issued a press release (the "Press Release") announcing that the independent Data and Safety Monitoring Board ("DSMB") for its ongoing PRECISE-AD Phase 1b clinical trial has unanimously recommended that the Company proceed to the third and final dose escalation cohort in this trial of PMN310, the Company's lead therapeutic candidate in development for the treatment of Alzheimer's disease. A copy of the Press Release is attached hereto as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On September 3, 2025, the Company issued the Press Release announcing that the DSMB for its ongoing PRECISE-AD Phase 1b clinical trial has unanimously recommended that the Company proceed to the third and final dose escalation cohort in this trial of PMN310, the Company's lead therapeutic candidate in development for the treatment of Alzheimer's disease. The recommendation followed a review of available safety data through Cohort 2, which has now been fully enrolled, with no cases of amyloid-related imaging abnormalities observed to date. Enrollment of patients into Cohort 3 is now underway, keeping the Company on track to deliver 6-month interim data in the second quarter of 2026 and final top-line results in the fourth quarter of 2026.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: September 3, 2025 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer